31.07.2023 | Letter to the Editor
Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases
Erschienen in: Annals of Hematology | Ausgabe 10/2023
Einloggen, um Zugang zu erhalten